Research News

TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia

This study, co-led by A/Prof Takaomi Sanda and A/Prof Allen Yeoh, delves into T-cell acute lymphoblastic leukemia (T-ALL), a difficult to treat form of blood cancer. In T-ALL, the mutated TAL1 gene switches on the enhMYCN, a gene regulatory signal which increases MYCN gene expression. T-ALL cells rely heavily on MYCN to grow. Targeting this pathway may offer a potential treatment approach for T-ALL.

Read more here: https://www.nature.com/articles/s41375-023-01993-y

Share this story:
Facebook
Twitter
LinkedIn

Related Research News

Research News

ZBTB48: A New On-Switch for the Immune Response

CIITA is the master regulator of MHC class-II immune genes that are important for defense mechanism against infections and cancer …

Read More →
Research News

Magnetic Field Therapy Improves Breast Cancer Treatment with Fewer Side Effects

Chemotherapy, although the first line of defense in cancer treatment, is indiscriminate and is damaging to the entire body, which, …

Read More →
Research News

Extracellular Vesicles: Key Players in Tumour Microenvironment and Drug Resistance

This research, led by N2CR members Prof Goh Boon Cher and Prof Shazib Pervaiz with Dr Jayshree Hirpara as the …

Read More →